BIOMAT Database Logo BIOMAT Database Logo

Myasthenia gravis associated with adrenocortical insufficiency. Report of two cases. 1985

P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas

Two cases of Addison's disease associated with myasthenia gravis are reported. This association has been described only rarely in the literature. In the first case, there were marked immunological abnormalities. It is most likely that the origin of the adrenocortical insufficiency in the second case is tuberculous. The pathogenetic mechanism of these associations is briefly discussed.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009157 Myasthenia Gravis A disorder of neuromuscular transmission characterized by fatigable weakness of cranial and skeletal muscles with elevated titers of ACETYLCHOLINE RECEPTORS or muscle-specific receptor tyrosine kinase (MuSK) autoantibodies. Clinical manifestations may include ocular muscle weakness (fluctuating, asymmetric, external ophthalmoplegia; diplopia; ptosis; and weakness of eye closure) and extraocular fatigable weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles (ocular myasthenia). THYMOMA is commonly associated with this condition. Anti-MuSK Myasthenia Gravis,MuSK MG,MuSK Myasthenia Gravis,Muscle-Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle-Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Generalized,Myasthenia Gravis, Ocular,Anti MuSK Myasthenia Gravis,Generalized Myasthenia Gravis,Muscle Specific Receptor Tyrosine Kinase Myasthenia Gravis,Muscle Specific Tyrosine Kinase Antibody Positive Myasthenia Gravis,Myasthenia Gravis, Anti-MuSK,Myasthenia Gravis, MuSK,Ocular Myasthenia Gravis
D011729 Pyridostigmine Bromide A cholinesterase inhibitor with a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. Mestinon,Pyridostigmine,Bromide, Pyridostigmine
D002800 Cholinesterase Inhibitors Drugs that inhibit cholinesterases. The neurotransmitter ACETYLCHOLINE is rapidly hydrolyzed, and thereby inactivated, by cholinesterases. When cholinesterases are inhibited, the action of endogenously released acetylcholine at cholinergic synapses is potentiated. Cholinesterase inhibitors are widely used clinically for their potentiation of cholinergic inputs to the gastrointestinal tract and urinary bladder, the eye, and skeletal muscles; they are also used for their effects on the heart and the central nervous system. Acetylcholinesterase Inhibitor,Acetylcholinesterase Inhibitors,Anti-Cholinesterase,Anticholinesterase,Anticholinesterase Agent,Anticholinesterase Agents,Anticholinesterase Drug,Cholinesterase Inhibitor,Anti-Cholinesterases,Anticholinesterase Drugs,Anticholinesterases,Cholinesterase Inhibitors, Irreversible,Cholinesterase Inhibitors, Reversible,Agent, Anticholinesterase,Agents, Anticholinesterase,Anti Cholinesterase,Anti Cholinesterases,Drug, Anticholinesterase,Drugs, Anticholinesterase,Inhibitor, Acetylcholinesterase,Inhibitor, Cholinesterase,Inhibitors, Acetylcholinesterase,Inhibitors, Cholinesterase,Inhibitors, Irreversible Cholinesterase,Inhibitors, Reversible Cholinesterase,Irreversible Cholinesterase Inhibitors,Reversible Cholinesterase Inhibitors
D005260 Female Females
D005455 Fluorescent Antibody Technique Test for tissue antigen using either a direct method, by conjugation of antibody with fluorescent dye (FLUORESCENT ANTIBODY TECHNIQUE, DIRECT) or an indirect method, by formation of antigen-antibody complex which is then labeled with fluorescein-conjugated anti-immunoglobulin antibody (FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT). The tissue is then examined by fluorescence microscopy. Antinuclear Antibody Test, Fluorescent,Coon's Technique,Fluorescent Antinuclear Antibody Test,Fluorescent Protein Tracing,Immunofluorescence Technique,Coon's Technic,Fluorescent Antibody Technic,Immunofluorescence,Immunofluorescence Technic,Antibody Technic, Fluorescent,Antibody Technics, Fluorescent,Antibody Technique, Fluorescent,Antibody Techniques, Fluorescent,Coon Technic,Coon Technique,Coons Technic,Coons Technique,Fluorescent Antibody Technics,Fluorescent Antibody Techniques,Fluorescent Protein Tracings,Immunofluorescence Technics,Immunofluorescence Techniques,Protein Tracing, Fluorescent,Protein Tracings, Fluorescent,Technic, Coon's,Technic, Fluorescent Antibody,Technic, Immunofluorescence,Technics, Fluorescent Antibody,Technics, Immunofluorescence,Technique, Coon's,Technique, Fluorescent Antibody,Technique, Immunofluorescence,Techniques, Fluorescent Antibody,Techniques, Immunofluorescence,Tracing, Fluorescent Protein,Tracings, Fluorescent Protein
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000224 Addison Disease An adrenal disease characterized by the progressive destruction of the ADRENAL CORTEX, resulting in insufficient production of ALDOSTERONE and HYDROCORTISONE. Clinical symptoms include ANOREXIA; NAUSEA; WEIGHT LOSS; MUSCLE WEAKNESS; and HYPERPIGMENTATION of the SKIN due to increase in circulating levels of ACTH precursor hormone which stimulates MELANOCYTES. Addison's Disease,Primary Adrenal Insufficiency,Primary Adrenocortical Insufficiency,Primary Hypoadrenalism,Addisons Disease,Adrenal Insufficiency, Primary,Adrenocortical Insufficiencies, Primary,Adrenocortical Insufficiency, Primary,Disease, Addison,Hypoadrenalism, Primary,Hypoadrenalisms, Primary,Insufficiencies, Primary Adrenocortical,Insufficiency, Primary Adrenocortical,Primary Adrenocortical Insufficiencies
D013934 Thymectomy Surgical removal of the thymus gland. (Dorland, 28th ed) Thymectomies

Related Publications

P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Ocular myasthenia gravis; report of two cases.
April 1949, American journal of ophthalmology,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
[Two cases of myasthenia gravis associated with transient amenorrhea].
May 1989, Rinsho shinkeigaku = Clinical neurology,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Myasthenia gravis and pipecuronium--report of two cases.
February 1992, Middle East journal of anaesthesiology,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Myasthenia gravis associated with adrenocortical insufficiency; report of a case with post-mortem findings and a review of the literature.
December 1950, The New England journal of medicine,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Two Cases of Myasthenia Gravis.
January 1924, Proceedings of the Royal Society of Medicine,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
[Two cases of myasthenia gravis].
January 1955, Journal des sciences medicales de Lille,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
MYASTHENIA GRAVIS AND HYPERTHYROIDISM. A REPORT OF TWO CASES.
November 1963, California medicine,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Juvenile ocular myasthenia gravis: a report of two cases.
January 2024, Digital journal of ophthalmology : DJO,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Estrogen therapy in myasthenia gravis; report of two cases.
April 1957, Missouri medicine,
P Dumas, and F Archambeaud-Mouveroux, and J M Vallat, and D Barussaud, and J Hugon, and M Dumas
Parkinson's disease associated with myasthenia gravis. A report of 4 cases.
June 2003, Journal of neurology,
Copied contents to your clipboard!